| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.002 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.006 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.006 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.15 | 0.007 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.007 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.007 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.09 | 0.009 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.01 |